TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016

TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016
Published Jun 30, 2016
46 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016, provides in depth analysis on TAR DNA-Binding Protein 43 (TDP-43) targeted pipeline therapeutics.

The report provides comprehensive information on the TAR DNA-Binding Protein 43 (TDP-43), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for TAR DNA-Binding Protein 43 (TDP-43)
- The report reviews TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics and enlists all their major and minor projects
- The report assesses TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to TAR DNA-Binding Protein 43 (TDP-43) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for TAR DNA-Binding Protein 43 (TDP-43)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of

  
Source:
Document ID
GMDHC0261TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
TAR DNA-Binding Protein 43 (TDP-43) Overview61
Therapeutics Development73
  TAR DNA-Binding Protein 43 (TDP-43) Products under Development by Stage of Development71
  TAR DNA-Binding Protein 43 (TDP-43) Products under Development by Therapy Area81
  TAR DNA-Binding Protein 43 (TDP-43) Products under Development by Indication91
TAR DNA-Binding Protein 43 (TDP-43) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
TAR DNA-Binding Protein 43 (TDP-43) Products under Development by Companies122
TAR DNA-Binding Protein 43 (TDP-43) Therapeutics Assessment145
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration161
  Assessment by Molecule Type172
TAR DNA-Binding Protein 43 (TDP-43) Companies Involved in Therapeutics Development195
  Biogen, Inc.191
  ImStar Therapeutics Inc.201
  Primary Peptides, Inc.211
  SK Biopharmaceuticals Co., Ltd.221
  TauRx Therapeutics Ltd.231
TAR DNA-Binding Protein 43 (TDP-43) Drug Profiles249
  IMS-088 Drug Profile241
  NI-205 Drug Profile251
  Small Molecule to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis Drug Profile261
  Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease Drug Profile271
  Small Molecules to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis Drug Profile281
  Synthetic Peptide to Inhibit TDP-43 for Amyotrophic Lateral Sclerosis Drug Profile291
  TRx-0237 Drug Profile303
TAR DNA-Binding Protein 43 (TDP-43) Dormant Projects331
TAR DNA-Binding Protein 43 (TDP-43) Featured News &Press Releases3411
  Nov 23, 2015: Aquinnah Pharmaceuticals Receives $680,000 Grant from NINDS To Advance New Therapies for ALS341
  Jan 20, 2015: First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer s Disease341
  Sep 25, 2014: Proteome Sciences signs $2m contract with Genting TauRx Diagnostic Centre to develop diagnostic panels to detect Alzheimer's disease and monitor treatment efficacy351
  Sep 22, 2014: TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX in Alzheimer's Disease361
  Jul 15, 2014: TauRx Therapeutics Achieves Enrolment Target in the First of Its Two Phase III Clinical Trials of LMTX in Alzheimer s Disease371
  Jun 18, 2014: University Hospitals Case Medical Center now enrolling patients in clinical trial for Frontotemporal Dementia381
  Mar 27, 2014: TauRx Chairman to present at scientific symposium focused on advances in Alzheimer's treatments391
  Mar 24, 2014: TauRx Therapeutics to present at Social Care Conference in London on 25th401
  Jan 09, 2014: First German Patients Enroll in Phase 3 Clinical Trials of LMTX for Alzheimer's Disease401
  Jan 06, 2014: TauRx Expands Alzheimer's Clinical Trials in the United States411
  Nov 26, 2013: ImStar Therapeutics Selects Lead Drug Candidate for ALS411
  Oct 03, 2013: Professor Claude Wischik, Chairman of TauRx, highlights future consequences of Alzheimer s Disease at annual psychogeriatric conference in Korea421
  Sep 19, 2013: TauRx achieves milestone in global Phase 3 clinical trials of LMTX for Alzheimer's Disease421
  Jun 10, 2013: TauRx Therapeutics And Toronto Memory Program Announce Canadian Launch Of Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease431
  May 22, 2013: TauRx Therapeutics Enrolls First Patient In Phase III Clinical Trials Of LMTX For Treatment Of Alzheimer's Disease In UK441
Appendix452
  Methodology451
  Coverage451
  Secondary Research451
  Primary Research451
  Expert Panel Validation451
  Contact Us451
  Disclaimer461

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/TAR-DNA-Binding-Protein-43-TDP-43-Pipeline-Review-H1-2016-2088-16128>
  
APA:
Global Markets Direct - Market Research. (2016). TAR DNA-Binding Protein 43 (TDP-43) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/TAR-DNA-Binding-Protein-43-TDP-43-Pipeline-Review-H1-2016-2088-16128>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.